AVAH vs CHE: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

Reading it: AVAH is the cheaper of the two on forward earnings, but cheaper is not the same as better. Pair the valuation with growth (how far the forward P/E sits below the trailing P/E) and risk (beta) before you decide.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. AVAH and CHE share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined AVAH and CHE exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Aveanna Healthcare Holdings runs home and community care across 39 states, with concentrations in Texas, Pennsylvania and California. The largest business by far is Private Duty Services, which supplies skilled private duty nursing, therapy, school nursing and personal care to medically complex and chronically ill children, and which produced ~$536 million of the ~$648 million of first-quarter 2026 revenue. A smaller Home Health and Hospice segment (~$67 million in the quarter) serves mostly elderly patients and is paid by Medicare, and a Medical Solutions segment (~$46 million) delivers enteral nutrition and related products. Gross margins differ sharply by segment: ~27.9% in private duty nursing, ~53.7% in home health and hospice, ~44.7% in medical solutions, so mix shifts move the consolidated number.

Full AVAH guide

Chemed Corporation runs two entirely unrelated businesses under one holding company. VITAS Healthcare, roughly two-thirds of revenue, is a leading provider of end-of-life hospice and palliative care, drawing well over 90% of its revenue from Medicare and Medicaid per-diem payments. Roto-Rooter, the remaining third, is the largest US provider of plumbing, drain cleaning, and water-damage restoration, serving both residential and commercial customers through company-owned operations and franchises. The two segments share little operationally but together produce steady consolidated cash flow that management returns via buybacks and a small dividend.

Full CHE guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• AVAH drivers: State Medicaid rate increases versus caregiver wages; Preferred payer agreements and government affairs.
• CHE drivers: VITAS hospice demand and aging demographics; Reduced Medicare Cap drag.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Payer concentration is the dominant risk: with ~81% of revenue tied to Medicaid and Medicaid managed care, a single adverse state budget or rate freeze reaches the income statement directly, and the Medicaid funding changes in the 2025 federal tax law leave states with less room to be generous. For CHE, vITAS derives the large majority of its revenue from Medicare and Medicaid, so reimbursement rate changes, the annual per-patient Cap, and policy shifts can materially affect results.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick AVAH if you believe its drivers more; CHE if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the AVAH and CHE guides.

AVAH. The trailing P/E near 10x looks cheaper than the business is, because 2025 GAAP net income was lifted by releasing a deferred tax valuation allowance; the forward P/E of about 13.7x on 2027 estimates ($0.91 per share) is the cleaner read. Enterprise value of roughly $4.1 billion against trailing EBITDA gives about 13.4x, a premium to slower Medicare home health peers after the 2026 rally. Consensus for 2026 revenue is about $2.69 billion, and the November 5, 2026 report is the next check on the spread and the debt load.

CHE. Chemed's revenue growth picked up to nearly 9% in the second quarter of 2026 and earnings beat estimates twice in a row, which helped lift the shares about 21% this year. At about 19 times forward earnings the stock prices in that recovery continuing, with analysts expecting 2026 EPS of about $25.49. The October 27, 2026 report (consensus EPS $6.44) will show whether VITAS volumes and Roto-Rooter demand held up in the third quarter.

Headline figures (approximate, October 2026): AVAH shows revenue (ttm) ~$2.6B through Q2 2026 (Q2 up ~13.7% year over year), q2 2026 eps $0.22 vs $0.17 consensus (Q1: $0.18 vs $0.13), net income (ttm) ~$275M (includes the 2025 non-cash tax benefit), margins (ttm) Gross ~32.0%, operating ~12.6%; CHE shows revenue (ttm) ~$2.6 billion; Q2 2026 ~$673 million, +8.8% YoY, net income (ttm) ~$275 million; trailing EPS ~$20.37, q2 2026 eps $6.06 vs $5.60 expected, margins Gross ~33%; operating ~13%; net ~10.6%.

AVAH and CHE are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined AVAH and CHE exposure against your real portfolio. It is not an investment adviser.